Skip to main content
OpenTrials
Completed

NCT Number: NCT04785703

Prolactin Hormone in Oral Lichen Planus

Oral lichen planus (OLP) is one of the most common mucosal diseases with autoimmune etio-pathogenesis with involvement of various cytokines similar to psoriasis.It generally occurs more commonly in females, in a ratio of 3:2. prolactin (PRL),It is a peptide hormone that has a role in autoimmune related diseases like systemic lupus erythematosus and , rheumatoid Artheritis. The role of PrL in OLP pathogenesis was never investigated.the aim of this study is to investigate the expression of PRL receptors in tissue biopsies of OLP patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

October University for modern sciences and arts

Giza, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with oral lichen planus
  • systemically healthy

Exclusion criteria

  • oral lichenoid lesions

Treatment and study plan

Primary outcomes

  1. prolactin receptors expression in oral mucous membrane

    Time frame: 24 hours

    immuno-histochemistry

Sponsors and collaborators

Lead sponsor

October University for Modern Sciences and Arts

Other

Collaborators

  • Al-Azhar University

Registry information

Official study title

Prolactin Hormone in Oral Lichen Planus Tissue Samples

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Mar 8, 2021
Registry last updated
Mar 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.